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To the Editor: Van Hasselt and colleagues report a ketoacidosis phenotype in carriers of null mutations in SLC16A1, encoding MCT1. They do not establish that loss of MCT1 directly impairs the ability of peripheral tissues to take up β-hydroxybutyrate or acetoacetate. It is conceivable that loss of MCT1 expression indirectly leads to ketoacidosis by altering the production of ketones -for example, by altering the delivery of branched-chain amino acid catabolites (ketoacids), which are major ketogenic substrates particularly in infants and children, to the liver. 1,2 Have the authors assessed β-hydroxybutyrate or acetoacetate uptake and catabolism in fibroblasts cultured from the study patients? At present, we would conclude from the hyperketonemic phenotype of the patients described only that MCT1 is not the major hepatic exporter of ketone bodies in humans. On the basis of my laboratory's zebrafish genetic studies of a null mutant of the orthologous gene slc16a6a, I suspect that human SLC16A6 (encoding MCT7) is the major hepatic ketone-body exporter. 3 I await identification and characterization of humans with SLC16A6 mutations. Amnon Schlegel, M.D., Ph.D.
As shown in Figure S2B and S2C in the Supplementary Appendix of the article (available at NEJM.org), there was no clear relation between glucose levels and the depth of ketoacidosis. Glucose levels actually were within the normal range (>4 mmol per liter) during most documented events. Ketoacidotic events were generally associated with reduced, but not absent, caloric intake, and events could be stopped only by supplying ample amounts of carbohydrates, in excess of the basal energy requirement. Our obser vations are in line with those in several other inborn errors of intermediary metabolism: metabolic derangements occur if -and are maintained as long as -the energy requirements are not met. 1 The energy requirement is known to be elevated during infections and to decrease with age, 1 providing an explanation for both risk factors.
We believe that our data are consistent with the concept that the metabolic derangement (i.e., ketoacidosis) is maintained as long as the body senses a low cellular energy status in peripheral tissues, regardless of the plasma glucose values. Under these low-insulin conditions, glucagon levels probably reflect a low cellular energy status. In patients with low insulin levels owing to diabetes mellitus, glucagon excretion correlates with the depth of ketoacidosis, 2 and ketoacidosis can be prevented by blocking the excretion of glucagon. 3 Schlegel suggests that the profound ketoacidosis observed in our patients may be an indirect effect of disturbances in the production, rather than utilization, of ketones. Following that line of reasoning, the loss-of-function mutations found in our patients would be expected to result in decreased import of substrates and, thus, decreased ketone formation, This would, in turn, lead to hypoketosis on fasting, not hyperketosis -a situation similar to the biochemical findings in ketogenesis defects and, perhaps, in a defect of ketone export. Even if the mutations would somehow lead to increased import, given the endocrine control of ketogenesis, that would have mild-to-moderate effects on ketones, at best. Peter M. van Hasselt, M.D., Ph.D.
